Patents Assigned to NeuroTherapeutics, Inc.
-
Patent number: 11179377Abstract: Provided are pharmaceutical compositions useful for the treatment and/or prevention of a disorder, such as addiction. For example, pharmaceutical compositions are provided that comprise a first active pharmaceutical component (e.g., metyrapone) and a second active pharmaceutical component (e.g., oxazepam). The compositions may be constructed in such a manner as to limit the physical contact between the first and second active pharmaceutical components, thus preventing any degradation of the active pharmaceutical components resulting form interaction between the two components. The compositions may include at least one pharmaceutically acceptable excipient. Also provided are methods of making the compositions as well as kits containing materials to provide the compositions.Type: GrantFiled: March 12, 2018Date of Patent: November 23, 2021Assignee: Embera NeuroTherapeutics, Inc.Inventors: Julie Straub, Muralikrishna Duvvuri, Parag M. Ved, Bruce Rehlaender, Jay Breaux, Winston A. Vadino, Kripanath Borah, Carol Gloff
-
Publication number: 20210353552Abstract: The present application discloses pharmaceutical compositions for modified release of huperzine. The pharmaceutical compositions and methods described herein, allow for dosing of huperzine at higher therapeutic thresholds, while avoiding rapid serum peak plasma levels, thereby avoiding the adverse nausea and vomiting associated with the immediate release pharmaceutical compositions. Methods of treating neurological disorders and/or seizure disorders with the modified release compositions is also described.Type: ApplicationFiled: July 28, 2021Publication date: November 18, 2021Applicant: Biscayne Neurotherapeutics, Inc.Inventors: Stephen D. Collins, Peter Goldstein, Joshua T. Johnstone
-
Publication number: 20200360400Abstract: The present invention is based, in part, on our discovery that certain types of therapeutic agents may be used in combination to treat a variety of neuropsychiatric and related disorders, including addiction (e.g., to a substance or activity) as well as to alleviate some symptoms associated with other diseases or conditions. Regardless of precise formulation, the compositions of the invention may include one ingredient that targets the hypothalamo-pituitary-adrenal (HPA) axis and at least one active ingredient that targets the prefrontal cortex. Either or both of these types of agents may be combined with an agent that inhibits activity in the sympathetic nervous system. Thus, the compositions or combination pharmacotherapies can also include an agent that inhibits a beta-adrenergic receptor or that otherwise acts as an antihypertensive or anxiolytic agent.Type: ApplicationFiled: May 18, 2018Publication date: November 19, 2020Applicant: Embera NeuroTherapeutics, Inc.Inventor: Michael Detke
-
Publication number: 20180185375Abstract: The present invention features a composition comprising a first agent and a second agent for treating disorder associated with aberrant activity in the HPA axis like an addiction to a substance (e.g., cocaine, amphetamines, methamphetamine, methylphenidate, heroin, codeine, hydrocodone, nicotine, alcohol, prescription medication (e.g., Percodan®, Percoset®), marijuana, tobacco, methadone, food), addiction to an activity (e.g., gambling, sex, eating), substance use disorders, mood disorders, anxiety disorders, bipolar disorder, sleep disorders, insomnia, posttraumatic stress syndrome, borderline personality disorder, disruptive behavior disorders, ADHD, major depressive disorder, burnout, chronic fatigue syndrome, fibromyalgia, irritable bowel syndrome, eating disorders (e.g., Prader Willi Syndrome), obesity, depression, menopause, premenstrual syndrome (PMS), obsessive compulsive disorder (OCD), social anxiety, generalized anxiety disorder, dysthymia, or schizophrenia.Type: ApplicationFiled: June 22, 2016Publication date: July 5, 2018Applicant: Embera Neurotherapeutics, Inc.Inventors: Michael Detke, Martin Phillips, Robert Linke
-
Patent number: 9987286Abstract: The present invention features, inter alia, pharmaceutically acceptable compositions that include metyrapol as the sole pharmaceutically active agent; compositions that include metyrapol and at least one additional pharmaceutically active agent; compositions in which the agent targeting the HPA axis is, itself, new or modified (e.g., a bi-specific antibody designed to traverse the blood-brain barrier or a known compound redesigned by, for example, conjugation to a substance that traverses the blood-brain barrier); and compositions in which the agent targeting the HPA axis is newly formulated in such a way that it fails to significantly inhibit cortisol production in the adrenal gland. For example, the composition can be formulated to include a dosage that is too low to reduce plasma cortisol levels or formulated to preferentially affect the skin.Type: GrantFiled: June 11, 2015Date of Patent: June 5, 2018Assignees: EMBERA NEUROTHERAPEUTICS, INC., BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY & AGRICULTURAL & MECHANICAL COLLEGEInventors: Nicholas E. Goeders, Barbara S. Fox, Glenn Guerin
-
Publication number: 20160038509Abstract: The present invention features, inter alia, pharmaceutically acceptable compositions that include metyrapol as the sole pharmaceutically active agent; compositions that include metyrapol and at least one additional pharmaceutically active agent; compositions in which the agent targeting the HPA axis is, itself, new or modified (e.g., a bi-specific antibody designed to traverse the blood-brain barrier or a known compound redesigned by, for example, conjugation to a substance that traverses the blood-brain barrier); and compositions in which the agent targeting the HPA axis is newly formulated in such a way that it fails to significantly inhibit cortisol production in the adrenal gland. For example, the composition can be formulated to include a dosage that is too low to reduce plasma cortisol levels or formulated to preferentially affect the skin.Type: ApplicationFiled: June 11, 2015Publication date: February 11, 2016Applicant: EMBERA NEUROTHERAPEUTICS, INC.Inventors: Nicholas E. Goeders, Barbara S. Fox, Glenn Guerin
-
Patent number: 9078886Abstract: The present invention features, inter alia, pharmaceutically acceptable compositions that include metyrapol as the sole pharmaceutically active agent; compositions that include metyrapol and at least one additional pharmaceutically active agent; compositions in which the agent targeting the HPA axis is, itself, new or modified (e.g., a bi-specific antibody designed to traverse the blood-brain barrier or a known compound redesigned by, for example, conjugation to a substance that traverses the blood-brain barrier); and compositions in which the agent targeting the HPA axis is newly formulated in such a way that it fails to significantly inhibit cortisol production in the adrenal gland. For example, the composition can be formulated to include a dosage that is too low to reduce plasma cortisol levels or formulated to preferentially affect the skin.Type: GrantFiled: June 16, 2011Date of Patent: July 14, 2015Assignees: Embera Neurotherapeutics, Inc., Board of Supervisors of Louisiana State University and Agricultural and Mechanical CollegeInventors: Nicholas E. Goeders, Barbara S. Fox, Glenn Guerin
-
Publication number: 20130303523Abstract: The present invention features, inter alia, pharmaceutically acceptable compositions that include metyrapol as the sole pharmaceutically active agent; compositions that include metyrapol and at least one additional pharmaceutically active agent; compositions in which the agent targeting the HPA axis is, itself, new or modified (e.g., a bi-specific antibody designed to traverse the blood-brain barrier or a known compound redesigned by, for example, conjugation to a substance that traverses the blood-brain barrier); and compositions in which the agent targeting the HPA axis is newly formulated in such a way that it fails to significantly inhibit cortisol production in the adrenal gland. For example, the composition can be formulated to include a dosage that is too low to reduce plasma cortisol levels or formulated to preferentially affect the skin.Type: ApplicationFiled: June 16, 2011Publication date: November 14, 2013Applicant: EMBERA NEUROTHERAPEUTICS, INC.Inventors: Nicholas E. Goeders, Barbara S. Fox, Glenn Guerin
-
Patent number: 5166207Abstract: A method for enhancing the systemic delivery of dextromethorphan for the treatment of a neurological disorder resulting in injury to nervous tissue, which comprises administering to a patient suffering from the disorder an amount of a cytochrome P450IID6 enzyme inhibitor, sufficient to block dextromethorphan metabolism, and an amount of dextromethorphan sufficient to treat the neurological disorder. Quinidine is particularly suitable for use in the method of the invention.Type: GrantFiled: June 17, 1991Date of Patent: November 24, 1992Assignee: NeuroTherapeutics, Inc.Inventor: Richard A. Smith